STOCK TITAN

Red Light Holland's FDA-Compliant, DEA-Registered Partner Irvine Labs Granted United States Controlled Substances Import Permit for the Company's Raw Psilocybin Truffles

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Red Light Holland (TRUFF) has achieved a significant milestone as its partner, Irvine Labs, secured a Controlled Substances Import Permit to import 3 kg of raw psilocybin truffles from the Netherlands to the United States. Irvine Labs, an FDA-compliant and DEA-registered facility in California, will use these materials to develop extended shelf-life microdosing capsules. The partnership aims to create standardized products from naturally occurring psilocybin for emerging markets and government-funded programs. This development follows the 2025 psilocybin DEA quotas announced in April. Irvine Labs holds comprehensive licenses for various controlled substances and will focus on preserving psilocybin from naturally derived compounds during product development and manufacturing.
Red Light Holland (TRUFF) ha raggiunto un traguardo importante grazie al suo partner, Irvine Labs, che ha ottenuto un Permesso per l'Importazione di Sostanze Controllate per importare 3 kg di tartufi di psilocibina grezzi dai Paesi Bassi agli Stati Uniti. Irvine Labs, una struttura conforme alla FDA e registrata presso la DEA in California, utilizzerà questi materiali per sviluppare capsule microdosate a lunga conservazione. La partnership punta a creare prodotti standardizzati a base di psilocibina naturale per mercati emergenti e programmi finanziati dal governo. Questo sviluppo segue le quote DEA per la psilocibina del 2025 annunciate in aprile. Irvine Labs possiede licenze complete per varie sostanze controllate e si concentrerà sulla conservazione della psilocibina derivata da composti naturali durante lo sviluppo e la produzione dei prodotti.
Red Light Holland (TRUFF) ha alcanzado un hito significativo ya que su socio, Irvine Labs, obtuvo un Permiso de Importación de Sustancias Controladas para importar 3 kg de trufas crudas de psilocibina de los Países Bajos a Estados Unidos. Irvine Labs, una instalación conforme a la FDA y registrada en la DEA en California, utilizará estos materiales para desarrollar cápsulas de microdosificación con vida útil prolongada. La asociación busca crear productos estandarizados a partir de psilocibina natural para mercados emergentes y programas financiados por el gobierno. Este avance sigue a las cuotas de psilocibina de la DEA para 2025 anunciadas en abril. Irvine Labs posee licencias completas para varias sustancias controladas y se centrará en preservar la psilocibina derivada de compuestos naturales durante el desarrollo y la fabricación de productos.
Red Light Holland(TRUFF)는 파트너인 Irvine Labs가 네덜란드에서 미국으로 3kg의 원시 실로시빈 트러플을 수입하기 위한 통제 물질 수입 허가를 확보함으로써 중요한 이정표를 달성했습니다. 캘리포니아에 위치한 FDA 준수 및 DEA 등록 시설인 Irvine Labs는 이 재료를 사용해 유통기한이 연장된 마이크로도징 캡슐을 개발할 예정입니다. 이 파트너십은 자연 발생 실로시빈으로부터 표준화된 제품을 신흥 시장과 정부 지원 프로그램을 위해 만들고자 합니다. 이번 발전은 4월에 발표된 2025년 실로시빈 DEA 할당량에 따른 것입니다. Irvine Labs는 다양한 통제 물질에 대한 종합적인 라이선스를 보유하고 있으며, 제품 개발 및 제조 과정에서 자연 유래 화합물로부터 실로시빈을 보존하는 데 주력할 것입니다.
Red Light Holland (TRUFF) a franchi une étape importante grâce à son partenaire, Irvine Labs, qui a obtenu un permis d'importation de substances contrôlées pour importer 3 kg de truffes de psilocybine brutes des Pays-Bas vers les États-Unis. Irvine Labs, une installation conforme à la FDA et enregistrée auprès de la DEA en Californie, utilisera ces matériaux pour développer des capsules de microdosage à durée de conservation prolongée. Ce partenariat vise à créer des produits standardisés à partir de psilocybine naturelle pour les marchés émergents et les programmes financés par le gouvernement. Cette avancée fait suite aux quotas de psilocybine de la DEA pour 2025 annoncés en avril. Irvine Labs détient des licences complètes pour diverses substances contrôlées et se concentrera sur la préservation de la psilocybine issue de composés naturels lors du développement et de la fabrication des produits.
Red Light Holland (TRUFF) hat einen bedeutenden Meilenstein erreicht, da sein Partner Irvine Labs eine Genehmigung für den Import kontrollierter Substanzen erhalten hat, um 3 kg roher Psilocybin-Trüffel aus den Niederlanden in die USA zu importieren. Irvine Labs, eine FDA-konforme und bei der DEA registrierte Einrichtung in Kalifornien, wird diese Materialien zur Entwicklung von Mikrodosierungskapseln mit verlängerter Haltbarkeit verwenden. Die Partnerschaft zielt darauf ab, standardisierte Produkte aus natürlich vorkommendem Psilocybin für aufstrebende Märkte und staatlich geförderte Programme zu schaffen. Diese Entwicklung folgt auf die im April angekündigten DEA-Quoten für Psilocybin im Jahr 2025. Irvine Labs verfügt über umfassende Lizenzen für verschiedene kontrollierte Substanzen und wird sich darauf konzentrieren, Psilocybin aus natürlich gewonnenen Verbindungen während der Produktentwicklung und -herstellung zu erhalten.
Positive
  • Secured crucial DEA import permit for 3 kg of psilocybin truffles, enabling US market entry
  • Partnership with FDA-compliant and DEA-registered Irvine Labs strengthens regulatory compliance
  • Development of extended shelf-life microdosing capsules could create competitive advantage
  • Potential access to emerging markets and government-funded pilot programs
Negative
  • Success depends on unproven preservation technology and manufacturing protocols
  • Strict regulatory environment could pose ongoing challenges
  • Product development and approval timeline remains uncertain
  • Red Light Holland is moving forward with the import of 3 kg (3000 grams) of raw psilocybin truffles from the Company's farm in The Netherlands to the United States, via a Controlled Substances Import Permit.
  • Following this major milestone approval, Red Light Holland will ship their carefully packaged raw psilocybin truffles to California based, Irvine Labs, for development of extended shelf-life microdosing capsules.

Toronto, Ontario--(Newsfile Corp. - May 21, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal, recreational market within the Netherlands, in compliance with all applicable laws is excited to announce that its research and development partner, Irvine Labs Inc. ("Irvine Labs"), an FDA-compliant and DEA-registered facility in California, United States has successfully received its Controlled Substances Import Permit for psilocybin raw materials (truffles) from the Company's farm in Horst, the Netherlands, following the 2025 psilocybin DEA quotas announced in April.

With both the DEA quota and import permit now secured, Irvine Labs and Red Light Holland will proceed with the shipment of 3 kg of raw psilocybin material from the company's farm in the Netherlands in the coming weeks.

Red Light Holland's partner, Irvine Labs is licensed for prescription and over-the-counter (OTC) drug manufacturing by the California Department of Public Health (CDPH) and is a DEA Schedule 1 Bulk drug cultivator, manufacturer, importer and exporter; including psilocybin, psilocin, marijuana, THC, extracts, DET, DMT, LSD, peyote and mescaline.

The Companies are thrilled to continue their advancement in R&D; including working diligently on the preservation of psilocybin from naturally derived compounds during product development and manufacturing. Through Red Light Holland's partnership with Irvine Labs and the implementation of proprietary preservation technology, Red Light Holland aims to develop precise dehydration, manufacturing and storage protocols that maintain the integrity of natural compounds while significantly extending product shelf life. Combined with research into advanced packaging solutions, these innovations represent a comprehensive approach to ensuring product stability and quality throughout the supply chain.

"We are thrilled to announce this major milestone in our partnership with Irvine Labs, as they have now received their import permit for 3 kg of psilocybin raw materials," said Todd Shapiro, CEO and Director of Red Light Holland. "This advancement comes at a significant time as we've seen growing institutional support for psilocybin research, including from the new U.S. Surgeon General and the Department of Veterans Affairs, which we applaud. With the Controlled Substances Import Permit secured, we can now ship our psilocybin raw materials from our Netherlands farm to Irvine's California Lab to begin development of extended shelf-life microdosing capsules. This is another critical step in our mission: from underground to mainstream, and as a Company we are very proud of our overall progress and focus on standardization of naturally occurring psilocybin as our R&D continues with the overall goal of access and making a positive impact."

Shaun Land, President of Irvine Labs, added, "Receiving the Controlled Substances Import Permit represents the final regulatory hurdle in our collaboration with Red Light Holland, at this stage. We are now ready to receive the 3 kg of raw materials from the Netherlands and begin our work. We have extensive experience working with naturally derived pharmaceutical ingredients and are excited to support Red Light Holland's microdosing program with our expertise in manufacturing and compliance, aiming to extend these innovative products stability and shelf life."

Red Light and Irvine Labs combined goal is to develop a commercialized and standardized product from the Company's psilocybin truffles farm grown truffles that can be legally exported to emerging markets and used in government-funded pilot programs and clinical trials within the United States.

About Irvine Labs

Irvine Labs was established in 1997. Since 2013, Irvine Labs has had a significant investment in medical research and development through its Pharmaceutical Biotechnology Division with a focus on natural medicines, including cannabis, cannabinoids, psilocybin, herbs and other sources of natural medicines. Irvine Labs is licensed for Prescription and Over-the-Counter (OTC) drug manufacturing by the California Department of Public Health (CDPH). Irvine Labs is a DEA Schedule 1 Bulk drug manufacturer, importer and exporter (including marijuana, THC, extracts, psilocybin, psilocin, DET, DMT, LSD, Peyote and Mescaline), and Schedule 1-5 testing lab.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co

Forward-Looking Statements and Cautionary Note

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.

The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and Irvine lab's development of the Company's psilocybin; the Company and the Company's partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company's planned psilocybin import following Irvine Labs' successful receipt of its 2025 psilocybin DEA quota and pending import permit approval; the Company's continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs Inc. and the research project to develop a process for the commercial manufacture of microdosing capsules derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the Company's ability to extract and expand access to psilocybin products; the Company's ability to successfully land the 3K shipment in the United States of America, the Company's ability to control the risk that the Controlled Substances Import Permit could become null and void and/or reversed; the Company's goals to standardize and sell advanced microdosing products to emerging markets or the United States for clinical trials or government funded programs; and the Company's ability to scalable production of high-quality, and approved microdoing capsules with extended shelf life via Irvine Labs ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the United States or around the world.

Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' abilities, including Irvine Labs to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's ability to realize its plans for its planned psilocybin imports following Irvine Labs' successful receipt of its 2025 psilocybin DEA quota and pending import permit approval; the Company's ability for its continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs and their research project to develop a process for the commercial manufacture of natural-source microdoing capsules derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the ability to extract and expand access to psilocybin products; the Company's ability to successfully land the shipment in the United States of America, the Company's goals to standardize and sell advanced microdosing products to emerging markets or the United States for clinical trials or government funded programs; the Company's ability to control the risk that the Controlled Substances Import Permit could become null and void and/or reversed; and the Company's ability to have scalable production of high-quality, microdosing capsules with extended shelf life for Global Distribution and The Company's ability to import their products into the United States and eventually the Companys ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the USA or around the world.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' inabilities, including Irvine Labs, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's inability to realize upon its plans for its planned psilocybin import despite Irvine Labs' successful receipt of its 2025 psilocybin DEA quota; delays or issues with the import permit process; the Company's inability to maintain its commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs; and The Company's ability to expand and extract access to psilocybin products.

The Company cannot make medical claims and is purely in a R&D phase with its partners Irvine Labs Inc.

Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252904

FAQ

What is the significance of TRUFF's DEA import permit for psilocybin truffles?

The permit allows Red Light Holland to legally import 3 kg of raw psilocybin truffles from Netherlands to the US, enabling development of extended shelf-life microdosing capsules and potential participation in government-funded programs.

What is Irvine Labs' role in Red Light Holland's psilocybin business?

Irvine Labs is TRUFF's FDA-compliant, DEA-registered partner responsible for developing extended shelf-life microdosing capsules using imported psilocybin truffles and implementing preservation technology.

How much psilocybin material will TRUFF import to the United States?

Red Light Holland will import 3 kg (3000 grams) of raw psilocybin truffles from their Netherlands farm to Irvine Labs in California.

What are Red Light Holland's plans for the imported psilocybin truffles?

The company plans to develop standardized products for emerging markets and government-funded pilot programs, focusing on creating extended shelf-life microdosing capsules.

What licenses does Irvine Labs hold for handling psilocybin?

Irvine Labs holds DEA Schedule 1 licenses for cultivation, manufacturing, importing, and exporting, plus CDPH licenses for prescription and OTC drug manufacturing.
Red Light Hollan

OTC:TRUFF

TRUFF Rankings

TRUFF Latest News

TRUFF Stock Data

8.41M
381.75M
6.52%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Toronto